Page last updated: 2024-08-21

pyrazines and prednisolone

pyrazines has been researched along with prednisolone in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.57)18.7374
1990's1 (3.57)18.2507
2000's8 (28.57)29.6817
2010's17 (60.71)24.3611
2020's1 (3.57)2.80

Authors

AuthorsStudies
Reich, AL; Vogel, PG1
Higuchi, C; Nakano, Y; Nihei, H; Nishimura, H; Omata, M; Sanaka, T; Shinobe, M; Sugino, N1
Dimopoulos, MA; Rahemtulla, A; Terpos, E1
De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N1
Okamoto, S1
Iida, S2
Ishida, T1
Higa, GM; Saad, AA; Sharma, M1
Kanda, Y1
Ozaki, S1
Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C1
Abdul-Jaleel, M; Candelaria-Quintana, D; Libby, E; Moualla, H; Rabinowitz, I1
Cheng, B; Cheung, YK; Lee, SM1
Anderson, K; Cakana, A; Deraedt, W; Dimopoulos, M; Esseltine, DL; Hou, J; Khuageva, N; Kropff, M; Liu, K; Mateos, MV; Petrucci, MT; Richardson, P; Robak, T; Rossiev, V; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H; Vekemans, MC1
Bolaman, Z; Dayanir, V; Dayanir, Y; Kadikoylu, G; Kocaturk, T; Yavasoglu, I1
Adachi, K; Endoh, A; Nakamura, R; Oda, Y; Ooi, S; Urushidani, Y1
Imagawa, J; Kimura, A; Kinoshita, M; Mihara, K; Mino, T; Sakai, A; Yoshida, T1
Suzuki, K1
Ando, K; Hotta, T; Iida, S; Ishii, M; Matsue, K; Matsumoto, M; Mukai, HY; Ogawa, Y; Ogura, M; Ohashi, K; Sakai, A; Suzuki, K; Terui, Y; Tobinai, K1
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S1
Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH1
Bryant, J; Clegg, A; Cooper, K; Picot, J1
Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N1
Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M1
Choi, JO; Jeon, ES; Kim, HJ; Kim, JS; Kim, K; Kim, SJ; Lee, GY; Lee, JE; Lee, JY; Lee, SY; Lim, SH; Min, JH1
Li, YL1
Chakraborty, U; Chandra, A; Ghosh, S; Ray, AK1

Reviews

9 review(s) available for pyrazines and prednisolone

ArticleYear
Current treatment options for myeloma.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine

2005
[Recent progress in diagnosis of and therapy for multiple myeloma].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Sep-10, Volume: 95, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide

2006
[Recent progress in the treatment of multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:2

    Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Design; Football; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Reference Standards; Thalidomide

2007
[Chemotherapy for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisolone; Pulse Therapy, Drug; Pyrazines; Thalidomide; Vincristine

2007
Treatment of multiple myeloma in the targeted therapy era.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning

2009
[Hematopoietic stem cell transplantation for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Discovery; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine

2009
[New treatment strategies for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine

2009
[Multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid

2012
Current therapeutic strategy for multiple myeloma.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2

    Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid

2013

Trials

4 trial(s) available for pyrazines and prednisolone

ArticleYear
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip
    Annals of hematology, 2010, Volume: 89, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisolone; Pyrazines; Thalidomide; Treatment Outcome

2010
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent
    British journal of haematology, 2011, Volume: 153, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Erythrocyte Transfusion; Female; Hematinics; Humans; Incidence; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Survival Rate; Thromboembolism

2011
Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.
    Cancer science, 2013, Volume: 104, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Treatment Outcome

2013
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    European journal of endocrinology, 2014, Volume: 170, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucocorticoids; Glucose Intolerance; Humans; Insulin Resistance; Islets of Langerhans; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prednisolone; Pyrazines; Sitagliptin Phosphate; Triazoles

2014

Other Studies

15 other study(ies) available for pyrazines and prednisolone

ArticleYear
[Lyell's syndrome. "Syndrome of the burned skin"].
    Munchener medizinische Wochenschrift (1950), 1969, Oct-31, Volume: 111, Issue:44

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Barbiturates; Child; Female; Germany, West; Glucose; Humans; Male; Mouth Mucosa; Phenazines; Prednisolone; Pyrazines; Stevens-Johnson Syndrome; Sulfonamides

1969
Therapeutic effect of a newly developed antioxidative agent (OPC-15161) on experimental immune complex nephritis.
    Nephron, 1997, Volume: 76, Issue:3

    Topics: Animals; Antioxidants; Dipyridamole; Free Radical Scavengers; Immune Complex Diseases; Kidney; Kidney Cortex; Lipid Peroxidation; Male; Malondialdehyde; Nephritis; Phosphatidylcholines; Prednisolone; Proteinuria; Pyrazines; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Superoxides

1997
Bortezomib-induced Sweet's syndrome.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases

2005
Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
    American journal of hematology, 2010, Volume: 85, Issue:9

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Melphalan; Prednisolone; Pyrazines; Remission Induction

2010
Continual reassessment method with multiple toxicity constraints.
    Biostatistics (Oxford, England), 2011, Volume: 12, Issue:2

    Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine

2011
Successful treatment of early relapse of ocular myeloma with bortezomib and steroid after autologous stem cell transplantation.
    Bratislavske lekarske listy, 2010, Volume: 111, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Eye Neoplasms; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Plasmacytoma; Prednisolone; Pyrazines; Recurrence; Stem Cell Transplantation

2010
[A case of aggressive multiple myeloma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prednisolone; Pyrazines

2011
[Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Hyperbilirubinemia; Leukemia, Plasma Cell; Prednisolone; Pyrazines; Severity of Illness Index; Treatment Outcome

2012
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10

    Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine

2013
Comparative cost-effectiveness models for the treatment of multiple myeloma.
    International journal of technology assessment in health care, 2014, Volume: 30, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom

2014
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
    International journal of hematology, 2014, Volume: 99, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome

2014
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases

2014
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2014, Volume: 21, Issue:4

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisolone; Pyrazines; Retrospective Studies

2014
[Analysis of bortezomib treatment efficacy and adverse reactions for patients with follicular lymphoma].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Epirubicin; Humans; Lymphoma, Follicular; Prednisolone; Pyrazines; Treatment Outcome; Vincristine

2015
Subacute thyroiditis as a presenting manifestation of COVID-19: a report of an exceedingly rare clinical entity.
    BMJ case reports, 2020, Dec-18, Volume: 13, Issue:12

    Topics: Amides; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Diagnosis, Differential; Glucocorticoids; Humans; Male; Middle Aged; Prednisolone; Pyrazines; Radionuclide Imaging; SARS-CoV-2; Thyroid Function Tests; Thyroid Gland; Thyroiditis, Subacute; Treatment Outcome; Ultrasonography, Doppler, Color

2020